Identification of tyrosine residues of importance for survival signaling through the scaffolding protein Gab2 in both wild-type FLT3 and the FLT3-ITD

被引：0
|
作者：
Masson, Kristina [1 ]
Liu, Tao [1 ]
Sun, Jianmin [1 ]
Ronnstrand, Lars [1 ]
机构：
[1] Lund Univ, Dept Lab Med, Malmo, Sweden
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1622
引用
收藏
页码：484A / 484A
页数：1
相关论文
共 50 条
  • [21] FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation
    Zhu, Ruiqi
    Li, Li
    Nguyen, Bao
    Seo, Jaesung
    Wu, Min
    Seale, Tessa
    Levis, Mark
    Duffield, Amy
    Hu, Yu
    Small, Donald
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
  • [22] Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591
    Vempati, Sridhar
    Reindl, Carola
    Wolf, Ulla
    Kern, Ruth
    Petropoulos, Konstantin
    Naidu, Vegi M.
    Buske, Christian
    Hiddemann, Wolfgang
    Kohl, Tobias M.
    Spiekermann, Karsten
    CLINICAL CANCER RESEARCH, 2008, 14 (14) : 4437 - 4445
  • [23] Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knockin mice
    Li, Li
    Bailey, Emily
    Greenblatt, Sarah
    Huso, David
    Small, Donald
    BLOOD, 2011, 118 (18) : 4935 - 4945
  • [24] Potent Graft-versus-Leukemia Effect after Reduced-Intensity Allogeneic SCT for Intermediate-Risk AML with FLT3-ITD or Wild-Type NPMI and CEBPA without FLT3-ITD
    Laboure, Gaelle
    Dulucq, Stephanie
    Labopin, Myriam
    Tabrizi, Reza
    Guerin, Estelle
    Pigneux, Arnaud
    Lafarge, Xavier
    Leguay, Thibaut
    Bouabdallah, Krimo
    Dilhuydy, Marie-Sarah
    Duclos, Cedric
    Lascaux, Axelle
    Marit, Gerald
    Mahon, Francois-Xavier
    Boiron, Jean-Michel
    Milpied, Noel
    Vigouroux, Stephane
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (12) : 1845 - 1850
  • [25] Synergistic Anti-Leukemic Activity with Combination of FLT3 Inhibitor Quizartinib and MDM2 Inhibitor Milademetan in FLT3-ITD Mutant/p53 Wild-Type Acute Myeloid Leukemia Models
    Andreeff, Michael
    Zhang, Weiguo
    Kumar, Prasanna
    Zernovak, Oleg
    Daver, Naval G.
    Isoyama, Takeshi
    Iwanaga, Kouichi
    Togashi, Noriko
    Seki, Takahiko
    BLOOD, 2018, 132
  • [26] Loss of the Wild-Type Allele Contributes to Myeloid Expansion and Disease Aggressiveness in FLT3/ITD Knock-in Mice
    Li, Li
    Bailey, Emily
    Greenblatt, Sarah M.
    Huso, David
    Small, Donald
    BLOOD, 2011, 118 (21) : 395 - 395
  • [27] Flt3 ligand induces tyrosine phosphorylation of Gab1 and Gab2 and their association with Shp-2, grb2, and P13 kinase
    Zhang, SL
    Broxmeyer, HE
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 277 (01) : 195 - 199
  • [28] SU5416 inhibits wild-type and activated mutant FLT3 signaling in leukemia cells.
    Yee, KW
    O'Farrell, A
    Smolich, B
    Cherrington, J
    McGreevey, L
    Wait, CL
    Griffith, DJ
    Heinrich, MC
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3769S - 3769S
  • [29] Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation
    Agrawal, S.
    Koschmieder, S.
    Baeumer, N.
    Reddy, N. G. P.
    Berdel, W. E.
    Mueller-Tidow, C.
    Serve, H.
    LEUKEMIA, 2008, 22 (01) : 78 - 86
  • [30] Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation
    S Agrawal
    S Koschmieder
    N Bäumer
    N G P Reddy
    W E Berdel
    C Müller-Tidow
    H Serve
    Leukemia, 2008, 22 : 78 - 86
12345